Part 2: Risk-based Quality Management Video (RBQM) Series

While patient safety remains the primary concern of guidance ICH E6, revision 3 further directs sponsors to include patients in the research process. In part two of our RBQM video series, Amy Kissam-Sands and Tim Audin, Senior Director, Global Biometrics Group Lead talk with Taren Grom, Editor, PharmaVOICE about how to implement a proactive risk-management approach and address patient input in study design.

Return to Insights Center

Related Insights

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Article

Australia: Infrastructure and Innovations for Clinical Trials

Aug 28, 2023

Blog

Including patients in DCT design

Sep 13, 2022

Article

Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct

Sep 14, 2021

Article

Three ways to work with the FDA for better patient-focused trials

Jul 29, 2021

Article

Decentralized trial tools and technologies are here to stay: A regulatory perspective

Jul 23, 2021

Blog

Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression

Apr 23, 2024

Blog

A patient-centric approach to managing clinical trial complexity

Jul 13, 2021